抗体偶联药物诱导的间质性肺病的发病机制

Pathogenesis of antibody–drug conjugates-induced interstitial lung disease

药物性间质性肺病(drug-induced interstitial lung disease,DI-ILD)是药物所致肺部不良事件的最常见形式,其最常见原因是抗癌药物。DI-ILD首次被确定为一种需要特别关注的不良事件是因抗体偶联药物(antibody-drug conjugates,ADC)。随着研发药物数量和种类的增多、多款ADC药物被批准或即将被批准用于临床治疗,DI-ILD引发了越来越多的关注。然而,ADC药物引发DI-ILD的机制尚未明确,本文就目前常见且应用广泛的抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)ADC药物DI-ILD的发生机制进行综述。

Drug-induced interstitial lung disease(DI-ILD)is the most common form of drug-induced pulmonary adverse events,with anticancer drugs being the primary cause.DI-ILD first gained attention as a notable adverse event due to the use of antibody-drug conjugates(ADC).As the development of drugs,particularly ADCs,continues to expand and more ADCs are approved or nearing approved for clinical use,DI-ILD has become an area of growing concern.However,the mechanisms by which ADCs induce ILD remain unclear.This article reviews the mechanisms of DI-ILD in the most commonly used ADCs targeting human epidermal growth factor receptor 2(HER2).